Functional heterogeneity of antiheparin-platelet factor 4 antibodies: Implications in the pathogenesis of the HIT syndrome

Clinical and Applied Thrombosis/Hemostasis

Volumn 5, Issue SUPPL. 1, 1999, Pages

  Ahmad, Sarfraz ^a   Walenga, Jeanine M ^a,c   Jeske, Walter P ^a   Cella, Giuseppe ^b   Fareed, Jawed ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antibodies; Heparin; Platelet factor 4; Platelet function; Thrombocytopenia

Indexed keywords

HEPARIN; IMMUNOGLOBULIN G ANTIBODY; THROMBOCYTE FACTOR 4;

ANTIBODY PRODUCTION; CONFERENCE PAPER; GENETIC HETEROGENEITY; HUMAN; IMMUNOPATHOGENESIS; PRIORITY JOURNAL; SEROTONIN RELEASE; THROMBOCYTOPENIA;

EID: 0032747473     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/10760296990050s107     Document Type: Conference Paper

References (31)

1. Warkentin TE, Kelton JG. Heparin and platelets. Hematol Oncol Clin North Am 1990;4: 243.
2. Messmore HL, Upadhyay G, Farid S, et al. Heparin-induced thrombocytopenia and thrombosis in cardiovascular surgery. In: Pifarré R, ed. New Anticoagulants for the Cardiovascular Patient. Philadelphia: Hanley & Belfus Inc., 1993:83.
3. Walenga JM, Bick RL. Heparin-induced thrombocytopenia, paradoxical thromboembolism and other side effects of heparin therapy. In: Bick RL, ed. The Medical Clinics of North America-Current Concepts of Thrombosis. Philadelphia: W.B. Saunders Co., 1998:635.
4. Greinacher A, Eckhardt T, Mussman J, et al. Pregnancy complicated by heparin associated thrombocytopenia management by a prospective in vitro selected heparinoid (ORG 10172). Thromb Res 1993;71:123.
5. Stewart MW, Etches WS, Boskhov LK, et al. Heparin-induced thrombocytopenia: an improved method of detection based on lumi-aggregometry. Br J Haematol 1995;91:173.
6. Wallis DE, Workman DL, Lewis BE, et al. Failure of earlier heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999;106:629.
7. Towne JB, Bernhard VM, Hussey C, et al. White clot syndrome. Arch Surg 1979;114:372.
8. Weismann RE, Tobin RW. Arterial embolism occurring systemic heparin therapy. Arch Surg 1958;76:219.
9. Moberg P, Geary V, Sheikh M. Heparin-induced thrombocytopenia: a possible complication of heparin-coated pulmonary artery catheters. J Cardiothorac Anesth 1990;4:266.
10. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992;68:95.
11. Amiral J, Marfaing-Koka A, Poncz M, et al. The biological basis of immune heparin-induced thrombocytopenia. Platelets 1998;9: 77.
12. Greinacher A, Michels I, Liebenhoff U, et al. Heparin-associated thrombocytopenia: immune complexes are attached to the platelet membrane by the negative charge of highly sulphated oligosaccharides. Br J Haematol 1993;84:711.
13. Greinacher A, Pötzsch B, Amiral J, et al. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multi-molecular PF-4 heparin complex as the major antigen. Thromb Haemost 1994;71:247.
14. Visentin GP, Ford SE, Scott JP, et al. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1995;93:81.
15. Brandt JT, Isenhart CE, Osborne JM, et al. On the role of platelet FcγRIIA phenotype in heparin induced thrombocytopenia. Thromb Haemost 1995;74:1564.
16. Carlsson LE, Santoso S, Baurichter G, et al. Heparin-induced thrombocytopenia: new insights into the impact of the FcγRIIa-R-H131 polymorphism. Blood 1998;92:1526.
17. Aster RH. Heparin-induced thrombocytopenia and thrombosis. N Engl J Med 1995;32:1374.
18. Walenga JM, Koza MJ, Lewis BE, et al. Relative heparin-induced thrombocytopenic potential of low molecular weight heparins and new antithrombotic agents. Clin Appl Thromb Hemost 1996;2(Suppl.1):S21.
19. Kelton JG, Smith JW, Warkentin TE, et al. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994;83:3232.
20. Mohanty JG, Elazhary Y. Purification of IgG from serum with caprylic acid and ammonium sulphate precipitation is not superior to ammonium sulphate precipitation alone. Comp Immunol Microbiol Infect Dis 1989;12:153.
21. Ahmad S, Jeske WP, Walenga JM, et al. Synthetic pentasaccharides do not cause platelet activation by anti-heparin-platelet factor 4 antibodies. Clin Appl Thromb Hemost 1999;5:(in press).
22. Amiral J, Pouplard C, Vissac AM, et al. Affinity purification of anti-heparin-platelet factor 4 antibodies developed in heparin-induced thrombocytopenia and separation into fractions with different activation effects on platelets. Br J Haematol 1999;(submitted).
23. Ahmad S, Walenga JM, Jeske WP, et al. Functional heterogeneity of anti-platelet factor 4-heparin antibodies in patients with heparin-induced thrombocytopenic syndrome. In: Talwar GP, Nath I, Ganguly NK, et al., eds. Proceedings of the International Congress of Immunology. Bolonga, Italy: 1998:907.
24. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of proteins utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248.
25. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986;67:27.
26. Walenga JM, Jeske WP, Wood JJ, et al. Laboratory tests for heparin-induced thrombocytopenia: a multicenter study. Semin Hematol 1999;36(Suppl1):22.
27. Brandt E, Flad HD. Structure and function of platelet-derived cytokines of the β- thromboglobulin/interleukin 8 family. Platelets 1992;3:295.
28. Nieduszynski I. General physical properties of heparin. In: Lane DA, Lindahl U, eds. Heparin - Chemical and Biological Properties, Clinical Applications. Boca Raton, FL: CRC Press, Inc., 1989: 51.
29. Brown KJ, Parish CR. Histidine-rich glycoprotein and platelet factor 4 mask heparan sulfate proteoglycans recognized by acidic and basic fibroblast growth factor. Biochemistry 1994;33:13918.
30. Hansell P, Maione TE, Borgstrom P. Selective binding of platelet factor 4 to regions of active angiogenesis in vivo. Am J Physiol 1995;269:H829.
31. Denton J, Lane DA, Thunberg L, et al. Binding of platelet factor 4 to heparin oligosaccharides. Biochem J 1983;209:455.